Table 3.
Circulating Markers
| Spironolactone n=28 | Placebo n=31 | ||||||
|---|---|---|---|---|---|---|---|
| BL | 24 wk | Δ | BL | 24 wk | Δ | P-Value | |
| hsCRP, mg/L | 0.97 (0.32, 1.85) | 2.39 (0.62, 6.12) | 0.28 (−0.21, 2.18) | 1.19 (0.52, 4.36) | 1.74 (0.62, 4.89) | 0.19 (−0.29, 1.1) | 0.04 |
| IL-6, pg/mL | 0.56 (0.39, 0.80) | 0.76 (0.52, 1.22) | 0.14 (0.00, 0.44) | 0.56 (0.32, 1.24) | 0.60 (0.40, 1.01) | 0.02 (−6.1, 3.9) | 0.2 |
| 8-isoprostane, pg/mL | 5.0 (3.8, 6.6) | 4.7 (4.1, 6.5) | −0.50 (−1.6, 1.3) | 4.7 (3.8, 5.8) | 5.2 (4.4, 6.7) | 0.90 (−0.80, 1.5) | 0.05 |
| PGF2a. pg/mL | 31.7 (11.6, 80.7) | 38.0 (13.7, 74.0) | −0.35 (−32.1, 13.6) | 21.3 (13.7, 53.8) | 34.0 (27.2, 51.2) | 3.8 (−6.8, 19.6) | 0.5 |
| PGD2, pg/mL | 85.7 (46.5, 163.7) | 94.5 (45.8, 141.7) | −7.3 (−51.5, 33.0) | 77.9 (55.3, 120.3) | 88.0 (59.4, 115.7) | −3.5 (−45.3, 50.1) | 0.9 |
| PGE2, pg/mL | 195.8 (49.0, 475.4) | 203.3 (110.5, 335.1) | 7.1 (−175.7, 73.7) | 133.0 (63.0, 300.8) | 158.9 (103.0, 229.0) | 7.2 (−134.4, 118.0) | 0.9 |
| 9-HODE, ng/mL | 13.3 (8.4, 21.0) | 10.2 (5.1, 14.6) | −5.1 (−10.0, 0.20) | 11.4 (7.1, 20.2) | 10.2 (6.9, 17.1) | −1.6 (−6.9, 3.1) | 0.3 |
| 13-HODE, ng/mL | 10.9 (7.6, 19.7) | 10.0 (8.1, 13.6) | −1.3 (−9.3, 3.7) | 9.6 (6.3, 16.8) | 9.9 (7.6, 14.8) | −0.2 (−6.1, 3.9) | 0.6 |
| 5-HETE, ng/mL | 2.1 (0.76, 2.9) | 2.2 (1.6, 2.6) | 0.33 (−0.82, 1.4) | 2.0 (1.1, 3.0) | 2.1 (1.1, 3.4) | 0.15 (−0.29, 1.3) | 0.7 |
| 8-HETE, ng/mL | 0.79 (0.45, 2.0) | 0.87 (0.65, 1.8) | 0.00 (−0.32, 0.41) | 0.58 (0.39, 0.87) | 0.84 (0.60, 1.2) | 0.21 (−0.21, 0.50) | 0.7 |
| 9-HETE, ng/mL | 4.1 (1.8, 6.5) | 2.9 (1.5, 5.2) | −0.67 (−3.5, 0.57) | 1.4 (1.0, 2.6) | 1.8 (1.3, 3.1) | 0.21 (−0.21, 0.50) | 0.2 |
| 11-HETE, ng/mL | 1.4 (0.58, 3.3) | 1.5 (0.80, 2.6) | 0.10 (−1.3, 0.67) | 1.1 (0.62, 2.2) | 1.3 (1.1, 2.0) | 0.41 (−0.96, 0.91) | 0.9 |
| 12-HETE, pg/mL | 63.8 (24.9, 138.8) | 72.9 (32.3, 139.1) | 0.65 (−48.7, 38.7) | 39.9 (18.3, 64.3) | 49.5 (27.5, 75.5) | 13.3 (−26.4, 33.2) | 0.5 |
| 8,9-EET, ng/mL | 4.8 (2.5, 13.6) | 5.6 (3.5, 12.6) | −0.40 (−4.4, 3.2) | 3.0 (1.8, 5.7) | 4.5 (2.7, 6.8) | 0.30 (−1.5, 2.1) | 0.9 |
| 11,12-EET, ng/mL | 1.4 (0.45, 4.4) | 1.5 (0.79, 2.3) | 0.13 (−2.0, 0.71) | 1.2 (0.48, 2.7) | 1.5 (0.98, 2.1) | 0.16 (−1.2, 0.95) | 0.7 |
| 14,15-EET, ng/mL | 1.3 (0.69, 2.2) | 1.0 (0.82, 1.6) | −0.08, (−1.1, 0.49) | 0.94 (0.62, 1.3) | 1.1 (0.87, 1.3) | 0.13 (−0.37, 0.53) | 0.2 |
| 5-HEPE, ng/mL | 0.84 (0.56, 1.1) | 0.68 (0.49, 1.2) | −0.22 (−0.57, 0.38) | 0.63 (0.41, 0.78) | 0.71 (0.60, 0.91) | 0.24 (−0.04, 0.46) | 0.08 |
| 12-HEPE, pg/mL | 38.3 (13.4, 80.4) | 51.0 (21.3, 84.6) | −11.60 (−40.2, 34.2) | 19.5 (10.8, 52.9) | 30.2 (19.9, 48.4) | 4.8 (−16.0, 28.4) | 0.5 |
Data are median [interquartile range]. P-value is a comparison of the change from baseline to 24 weeks (Δ) between the 2 groups using log-transformed values. Non-normally distributed variables were log-transformed prior to analysis.
hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; PGF2α, prostaglandin F2α; PGD2, prostaglandin D2; PGE2, prostaglandin E2; HODE, hydroxyoctadecadienoic acid; HETE, hydroxyeicosatetraenoic acid; EET epoxyeicosatrienoic acid; HEPE, hydroxyeicosapentanoic acid.